TY - JOUR
T1 - Bacteriophage defends murine gut from Escherichia coli invasion via mucosal adherence
AU - Wu, Jiaoling
AU - Fu, Kailai
AU - Hou, Chenglin
AU - Wang, Yuxin
AU - Ji, Chengyuan
AU - Xue, Feng
AU - Ren, Jianluan
AU - Dai, Jianjun
AU - Barr, Jeremy J.
AU - Tang, Fang
N1 - Funding Information:
This study was supported by the National Key R&D Program of China (2023YFD1800300) and National Natural Science Foundation of China (32172858). We thank Dr. Nannan Wu of CreatiPhage Biotechnology for giving us 10 E.coli strains including 029 from humans, Professor Huanming Xia of Nanjing University of Science and Technology for providing us with a platform for chip fabrication, and Zhiyu Shi from the instrument platform of Institute of Immunology, College of Veterinary Medicine, Nanjing Agricultural University for assistance in using laser confocal microscope (Nikon A1).
Publisher Copyright:
© The Author(s) 2024.
PY - 2024/12
Y1 - 2024/12
N2 - Bacteriophage are sophisticated cellular parasites that can not only parasitize bacteria but are increasingly recognized for their direct interactions with mammalian hosts. Phage adherence to mucus is known to mediate enhanced antimicrobial effects in vitro. However, little is known about the therapeutic efficacy of mucus-adherent phages in vivo. Here, using a combination of in vitro gastrointestinal cell lines, a gut-on-a-chip microfluidic model, and an in vivo murine gut model, we demonstrated that a E. coli phage, øPNJ-6, provided enhanced gastrointestinal persistence and antimicrobial effects. øPNJ-6 bound fucose residues, of the gut secreted glycoprotein MUC2, through domain 1 of its Hoc protein, which led to increased intestinal mucus production that was suggestive of a positive feedback loop mediated by the mucus-adherent phage. These findings extend the Bacteriophage Adherence to Mucus model into phage therapy, demonstrating that øPNJ-6 displays enhanced persistence within the murine gut, leading to targeted depletion of intestinal pathogenic bacteria.
AB - Bacteriophage are sophisticated cellular parasites that can not only parasitize bacteria but are increasingly recognized for their direct interactions with mammalian hosts. Phage adherence to mucus is known to mediate enhanced antimicrobial effects in vitro. However, little is known about the therapeutic efficacy of mucus-adherent phages in vivo. Here, using a combination of in vitro gastrointestinal cell lines, a gut-on-a-chip microfluidic model, and an in vivo murine gut model, we demonstrated that a E. coli phage, øPNJ-6, provided enhanced gastrointestinal persistence and antimicrobial effects. øPNJ-6 bound fucose residues, of the gut secreted glycoprotein MUC2, through domain 1 of its Hoc protein, which led to increased intestinal mucus production that was suggestive of a positive feedback loop mediated by the mucus-adherent phage. These findings extend the Bacteriophage Adherence to Mucus model into phage therapy, demonstrating that øPNJ-6 displays enhanced persistence within the murine gut, leading to targeted depletion of intestinal pathogenic bacteria.
UR - http://www.scopus.com/inward/record.url?scp=85195252617&partnerID=8YFLogxK
U2 - 10.1038/s41467-024-48560-2
DO - 10.1038/s41467-024-48560-2
M3 - Article
C2 - 38834561
AN - SCOPUS:85195252617
SN - 2041-1723
VL - 15
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 4764
ER -